FDA COX-2 Review Will Include Input From Furberg, Full Rx Safety Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
After initially being asked not to appear at the meeting, Wake Forest's Furberg is formally re-invited to participate at the Feb 16-18 advisory committee meeting. FDA first invited only two members of the drug safety committee but has expanded its invitation to the full committee.
You may also be interested in...
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.
COX-2 Use Should Be Limited, FDA Advisory Cmte. Member Furberg Says In NEJM
Drug Safety & Risk Management Committee member Furberg advocates using lowest effective dose for short-term use when a COX-2 inhibitor is needed. Furberg's editorial in the New England Journal of Medicine was released on the eve of the COX-2 advisory committee meeting.
FDA Drug Safety Advisory Cmte. Adds Harvard's Platt Ahead Of COX-2 Review
Platt, who joined FDA's Drug Safety & Risk Management Advisory Committee in July 2004, is a member of the national steering committee for AHRQ's Centers for Education & Research in Therapeutics. His research at Harvard centers on using health plan data to improve drug safety and assess drug efficacy.